Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 200,918 | 220,943 | 0 | 0 | 0 |
| Marketable Securities | 13,053 | 23,130 | 0 | 0 | 0 |
| Other current assets | 5,855 | 5,944 | 0 | 0 | 0 |
| TOTAL | $219,826 | $250,017 | $0 | $0 | $0 |
| Non-Current Assets | |||||
| PPE Net | 7,573 | 8,007 | N/A | N/A | N/A |
| Other Non-Current Assets | 7,141 | 7,278 | 0 | 0 | 0 |
| TOTAL | $14,714 | $15,285 | $N/A | $N/A | $N/A |
| Total Assets | $234,540 | $265,302 | $0 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,810 | 3,313 | 0 | 0 | 0 |
| Accrued Expenses | 12,283 | 16,564 | 0 | 0 | 0 |
| TOTAL | $25,231 | $30,274 | $0 | $0 | $0 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 7,581 | 7,891 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 10,450 | 10,750 | 0 | 0 | 0 |
| TOTAL | $14,089 | $14,989 | $N/A | $N/A | $N/A |
| Total Liabilities | $39,320 | $45,263 | $0 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,526 | N/A | N/A | N/A | N/A |
| Common Shares | 4 | 4 | 0 | 0 | 0 |
| Retained earnings | -202,414 | -174,740 | 0 | 0 | 0 |
| Other shareholders' equity | -227 | -188 | 0 | 0 | 0 |
| TOTAL | $195,220 | $220,039 | $0 | $0 | $0 |
| Total Liabilities And Equity | $234,540 | $265,302 | $0 | $0 | $0 |